Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
6.570
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Macy's, Acuity Brands And 3 Stocks To Watch Heading Into Monday
January 09, 2023
With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
January 06, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
November 22, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
What 8 Analyst Ratings Have To Say About Revance Therapeutics
November 09, 2022
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
November 17, 2022
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body....
Via
FinancialNewsMedia
Exposures
COVID-19
Revance to Participate in the Stifel 2022 Healthcare Conference
November 09, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
November 08, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Therapeutics's Earnings: A Preview
November 07, 2022
Revance Therapeutics (NASDAQ:RVNC) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Revance...
Via
Benzinga
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
November 04, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
November 01, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
October 20, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
October 17, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
What 7 Analyst Ratings Have To Say About Revance Therapeutics
October 11, 2022
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
October 10, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
October 04, 2022
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
September 30, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022
September 22, 2022
Upgrades
Via
Benzinga
What 6 Analyst Ratings Have To Say About Revance Therapeutics
September 22, 2022
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
September 21, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal
September 19, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)
September 15, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 15, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 13, 2022
Via
Benzinga
Relay Therapeutics, Rent the Runway And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
September 13, 2022
U.S. stock futures traded higher this morning ahead of the much-awaited inflation data for August. Here are some big stocks moving lower in today’s pre-market trading session.
Via
Benzinga
Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket
September 13, 2022
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average...
Via
Benzinga
Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock
September 12, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
September 12, 2022
Gainers OpGen (NASDAQ:OPGN) shares rose 20.6% to $0.52 during Monday's after-market session. This security traded at a volume of 927.4K shares come close, making up 324.6% of its average volume over...
Via
Benzinga
Revance Announces Proposed Public Offering of Common Stock
September 12, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.